Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4016 Target Snapshot

Glutamate receptor 2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
456Compounds
105Assays
1Approved Drugs
579.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Glutamate receptor 2 shows clinical signal disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P42262. Start with amyotrophic lateral sclerosis, then reuse UniProt P42262 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with amyotrophic lateral sclerosis, then reuse UniProt P42262 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
amyotrophic lateral sclerosis

Glutamate receptor 2 shows clinical signal disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with amyotrophic lateral sclerosis because it currently carries clinical signal support. Linked drugs include TALAMPANEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glutamate receptor 2 as ChEMBL target CHEMBL4016, mapped to UniProt P42262. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glutamate receptor 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4016
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P42262
Glutamate receptor 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glutamate receptor 2 is the right protein anchor across sources, using UniProt P42262 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why amyotrophic lateral sclerosis is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGlutamate receptor 2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP42262
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlutamate receptor 2
UniProt AccessionP42262
Component TypeProtein
Sequence Length883 aa

Glutamate receptor 2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Glutamate receptor 2, mapped to UniProt P42262. Sequence length is 883 aa.

Mapped IDP42262
Review nameGlutamate receptor 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Glutamate receptor 2 shows clinical signal disease relevance led by amyotrophic lateral sclerosis. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
amyotrophic lateral sclerosis
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
anaplastic astrocytoma
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
anaplastic oligodendroglioma
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
Central Nervous System Neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
epilepsy
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Clinical signal Phase II
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugTALAMPANEL
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with amyotrophic lateral sclerosis because it currently carries clinical signal support. Linked drugs include TALAMPANEL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseamyotrophic lateral sclerosis
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
2
Phase III
3
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC5047.0
KI135.0
EC50393.0
KD4.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4218628 8.9 EC50 1.259 Preclinical
CHEMBL4091984 8.7 EC50 1.995 Preclinical
CHEMBL3088070 8.52 Ki 3.0 Preclinical
CHEMBL370038 8.41 Ki 3.89 Preclinical
CHEMBL4202524 7.87 EC50 13.4 Preclinical
CHEMBL331696 7.78 Ki 16.7 Preclinical
CHEMBL276815 7.78 Ki 16.8 Preclinical
CHEMBL13378 7.77 Ki 17.0 Preclinical
CHEMBL331644 7.71 Ki 19.3 Preclinical
CHEMBL123132 7.6 Ki 25.1 Preclinical
Distribution

pChEMBL Value Distribution

83
5.0
83
5.5
83
6.0
37
6.5
23
7.0
8
7.5
1
8.0
5
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

105
Total Assays
302
Tested Compounds
3
Assay Types
Binding — 85 assays, 302 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 58 162 5.5
single protein format 26 140 5.5
protein complex format 1 0 —
Functional — 16 assays, 41 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 14 37 6.3
assay format 2 4 6.3
ADME — 4 assays, 11 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 4 11 5.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine